Abstract
Gliomas are malignant primary brain tumors with poor prognosis. Recently, research was indicative of a tight connection between tumor malignancy and genetic alterations. Here, we propose an oncogenic implication of transforming acidic coiled-coil-containing protein 3 (TACC3) in gliomas. By comprehensively analyzing the Chinese glioma genome atlas (CGGA) and publicly available data, we demonstrated that TACC3 were overexpressed along with glioma grade and served as an independent negative prognostic biomarker for glioma patients. Functions’ annotations and gene sets’ enrichment analysis suggested that TACC3 may participate in cell cycle, DNA repair, epithelium-mesenchymal transition and other tumor-related biological processes and molecular pathways. Patients with high TACC3 expression showed CD133+ stem cell properties, glioma plasticity and shorter overall survival time under chemo-/radio-therapy. Additionally, a TACC3 associated the miRNA-mRNA network was constructed based on in silico prediction and expression pattern, which provide a foundation for further detection of TACC3-miRNA-mRNA axis function. Collectively, our observations identify TACC3 as an oncogene of tumor malignancy, as well as a prognostic and motoring biomarker for glioma patients.
Highlights
Glioma is the most common and devastating primary brain tumor characterized by high infiltration, rapid progression and relative resistance to radiotherapy and most chemotherapeutic agents [1,2,3]
Our observations explicitly showed that along with transforming acidic coiled-coil-containing protein 3 (TACC3) upregulation, patients were prone to be with the G3 subtype, classical/mesenchymal subtype and high grade glioma (Figure 3 and Table 2)
Our observations suggested that patients with high TACC3 expression possessed the CD133+ property
Summary
Glioma is the most common and devastating primary brain tumor characterized by high infiltration, rapid progression and relative resistance to radiotherapy and most chemotherapeutic agents [1,2,3]. Comprehensive multimodal treatments have been adopted, the outcomes for glioma patients remain poor. According to Chinese glioma genome atlas (CGGA) statistics, the overall survival (OS) times for glioblastoma (GBM, World Health Organization (WHO) Grade IV) patients is only 14.4 months, while the 6-month, 1-, 3- and 5-year OS rates were 87%, 61%, 15% and 9%, respectively [4]. With the evolution of biomedical techniques, especially the development of multidimensional omics platforms, some neuropathological biomarkers and molecular classification of glioma have been established. The identification of efficient diagnostic, prognostic and therapeutic biomarker and therapy targets remains crucial for glioma-tailored medicine.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
